IMNN.NASDAQImunon, INC

Form 4: Imunon Inc. Executive Granted Stock Options

Sentiment:

SEC Form 4 Filing


Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., was granted stock options for 25,000 shares on March 14, 2025, according to a Form 4 filing.

Summary

  • Khursheed Anwer, the Chief Scientific Officer of Imunon, Inc., was granted stock options to purchase 25,000 shares of common stock.
  • The options were granted on March 14, 2025, with an exercise price of $0.8651 per share.
  • The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary.
  • A Power of Attorney was executed on March 17, 2025, authorizing Susan Eylward and others to act on Khursheed Anwer's behalf for SEC filings related to Imunon, Inc. securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a common practice and generally viewed as a positive incentive for executives.

Positives

  • The grant of stock options aligns the executive's interests with those of the shareholders.
  • The vesting schedule encourages continued service and contribution to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

  • Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
  • Companies like Amgen, Gilead, and Biogen also utilize stock options to align executive compensation with shareholder value.
  • The vesting schedule of these options is typical, encouraging long-term commitment from the executive.

Stakeholder Impact

  • Shareholders may view the stock option grant as a positive incentive for the executive to improve company performance.
  • Employees may see the grant as a sign of confidence in the company's future.

Key Dates

DateDescription
03/14/2024Date of stock option grant
03/14/2025Date of earliest transaction (stock option grant) and first vesting date (1/2 of options)
03/14/2025One year anniversary of the date of grant, 1/4 of options vest
03/17/2025Date of Power of Attorney execution
03/18/2025Date of Form 4 signature
03/14/2026Two year anniversary of the date of grant, 1/4 of options vest
03/14/2035Expiration date of the stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.